Firefly&#39;s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members  Partnership Represents a Significant Expansion of Company&#39;s Commercial

AIFF

Firefly Confirms Public-Private Partnership with the Department of War

Firefly Expands Government Footprint with DoW Partnership for PTSD Treatment

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Firefly&amp;#39;s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company&amp;#39;s Commercial
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Firefly Neuroscience has established a partnership with the Department of War to enhance assessment and treatment for PTSD and TBI among U.S. service members. This collaboration leverages Firefly&#039;s FDA-cleared AI technology, positioning the company favorably in a lucrative government health market, ultimately expected to boost revenue and expand their market reach.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Firefly partners with the Department of War for PTSD and TBI treatment.</li><li>The partnership expands Firefly&#039;s outreach in U.S. government health sectors.</li><li>Firefly&#039;s FDA-cleared technology addresses U.S. military mental health challenges.</li><li>High incidence of TBI supports the need for Firefly&#039;s diagnostic tools.</li><li>Firefly has the world&#039;s largest standardized EEG/ERP database.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Firefly Neuroscience (AIFF): AIFF is positioned for growth through its governmental partnerships and significant market potential.</li><li>Evoke Neuroscience, Inc. (N/A): Acquisition provided Firefly with foundational technology for the DoW project.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 The article falls under &#039;Corporate Developments&#039; as it highlights a significant new partnership that could drive future revenue. This alignment with a critical government agency supports Firefly&#039;s innovation focus and underscores its role in addressing a pressing health issue.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Partnership could unlock millions in government contracts addressing military mental health.</li><li>Increased focus on mental health solutions could lead to substantial revenue growth.</li><li>Expansion into U.S. government markets might attract additional strategic partnerships.</li><li>Positive outcomes in partnership may enhance share valuation in the coming quarters.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Firefly&#039;s technology is FDA 510(k)-cleared and non-invasive.</li><li>The economic burden of PTSD in the military is approximately $42.7 billion.</li><li>Over 444,300 service members diagnosed with TBI from 2000 to 2021.</li><li>Firefly&#039;s repository consists of over 191,000 EEG/ERP brain scans.</li><li>The U.S. government is significantly increasing investment in military brain health.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Invest in AIFF as partnership may significantly enhance revenue prospects over the next year.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company's Commercial Footprint into the U.S. Government and Defense Health Sectors KENMORE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AIFF">AIFF</a>) ("Firefly," or the "Company"), today announced a partnership with the Department of War ("DoW") to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder ("PTSD") and/or Traumatic Brain Injury ("TBI"). The genesis of this innovative public-private brain health partnership was initial work by the founders of Evoke Neuroscience, Inc. (acquired by Firefly in May 2025) with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements. Addressing a Multi-Billion Dollar Military Mental Health Crisis PTSD and TBI represent two of the most significant and pervasive health challenges facing the U.S. military. The total excess economic burden of PTSD in the United States has been estimated at $232.2 billion, of which approximately $42.7 billion is attributed directly to the military population.1 In contrast to PTSD, the incidence of TBI is higher among military than civilian populations, in part because of the physical demands of military service and the potentially dangerous activities associated with military operations and training.2 According to the RAND Corporation, more than 444,300 U.S. service members were diagnosed with at least one TBI between 2000 and 2021.3 Despite the scale of this public and military health burden, objective, biomarker-driven diagnostic tools have remained largely absent from standard care — a gap that Firefly's EEG/ERP technology is intended to help address. FDA-Cleared AI Technology Supporting DoW Programs Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP platform is being utilized across related DoW programs, providing military healthcare providers with objective, quantitative neurological data intended to support more precise diagnosis, individualized treatment planning, and measurable outcomes tracking. The platform is non-invasive, scalable across both clinical and operational environments, and designed for real-world deployment at scale. The DoW partnership represents a potentially significant channel for Firefly's commercial strategy, expanding the Company's footprint into the U.S. government and defense health sectors. "Every U.S. service member who comes home carrying the invisible wounds of PTSD and/or TBI deserves to be truly seen — not just screened," commented Dave DeCaprio, President and Chief Operating Officer of Firefly. "This partnership reflects our core mission: to bring the most advanced, objective brain health tools to the people who need them most, so that military healthcare providers may act earlier, treat more precisely, and give people a real path forward. We are proud that Firefly's technology is being trusted to serve those who have sacrificed so much for this country." "We believe that this ongoing strategic partnership positions us well to benefit from the significant and growing U.S. government investment in military brain health — with a validated, FDA-cleared platform," said Firefly's Chief Executive Officer, Greg Lipschitz. "Our work with U.S. service members also complements our strategic initiative to build a proprietary foundation model of the human brain by combining a rapidly growing repository of brain scan data and important access to <a href="https://www.globenewswire.com/Tracker?data=Qn60Un3uuXW2wAtT2jPQHcAFggRTKdI_CCSyFl7fVJZaR1DfN8TYuAX9IFEM0yz9OrwskGbB1gu6r8zBKRk4Bc0ca90YaT_m7rZq89Wqtmr4kwicZIRfCHapIn4EmCfjAnShV7_C_iUEHmJt0SgjIXL06AODuX7QUwO9DP9iwWb8No4gSVKwM5fMN2TFn_av" rel="nofollow" target="_blank">NVIDIA GPU acceleration</a> to power next-generation EEG/ERP processing." Sources 1 Davis LL, Schein J, Cloutier M, et al. "The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective." The Journal of Clinical Psychiatry, 2022. 2 Haarbauer-Krupa J, et al "Epidemiology of Chronic Effects of Traumatic Brain Injury.&#34; J Neurotrauma, 2021. 3 RAND Corporation. "Improving Care for Veterans with Traumatic Brain Injury Across the Lifespan." Commissioned by Wounded Warrior Project, 2022. About Firefly Neuroscience Firefly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AIFF">AIFF</a>) is an Artificial Intelligence ("AI") company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly's proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world's largest known standardized EEG/ERP repository. Firefly's EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Please visit <a href="https://www.globenewswire.com/Tracker?data=YA8y7jTzI8wdCflcP_US_J6t3ztUTxXQefiNcDr9artNmYW3wud4k1UDCX_chmV6Xo7nA2Hj731fpnR6Lwav0jYZlXsgQ1e2ROzFwKO5emQ=" rel="nofollow" target="_blank">www.fireflyneuro.com</a> for more information. Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly's management team's expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor &amp; Media Contact Stephen Kilmer (646) 274-3580 stephen.kilmer@fireflyneuro.com <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTA3NCM3NTA1MTkwIzIyOTIyODQ="></img> <img alt="" src="https://ml.globenewswire.com/media/YzMzZWYwNDUtOWIxYy00MmIwLTgwZjItNjkzYWFjYjc2ODQ3LTEzMDM4MzQtMjAyNi0wMy0yNi1lbg==/tiny/Firefly-Neuroscience-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/cd317e6a-730f-4537-a096-9b724abb964e"><img src="https://ml.globenewswire.com/media/cd317e6a-730f-4537-a096-9b724abb964e/small/firefly-png.png" border="0" width="108" height="73" alt="Primary Logo"></img></a>

Firefly Neuroscience has established a partnership with the Department of War to enhance assessment and treatment for PTSD and TBI among U.S. service members. This collaboration leverages Firefly's FDA-cleared AI technology, positioning the company favorably in a lucrative government health market, ultimately expected to boost revenue and expand their market reach.

Firefly Confirms Public-Private Partnership with the Department of War

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News